🟠 Moderate Evidence
A cross-sectional analysis of 841 European adults published in Alzheimer’s & Dementia (2025, PMID: 40832908) provides the first direct evidence that age-related changes in blood lipids may explain why women face disproportionately higher Alzheimer’s disease risk. Researchers found that women with Alzheimer’s showed a marked depletion of protective unsaturated fats—particularly omega-3-rich lipids—while men with the disease showed no such pattern.
Key takeaways
- Women with Alzheimer’s had significantly lower blood levels of protective omega-3 lipids compared to healthy women, while men showed no similar decline
- The loss of estrogen after menopause weakens the brain’s ability to synthesize and transport long-chain omega-3s (DHA), dismantling a biochemical advantage women naturally possess
- A separate meta-analysis of 58 randomised controlled trials found that 1,000–2,500 mg/day of combined EPA and DHA showed the strongest cognitive benefits in healthy adults, not in those already diagnosed
- The findings are observational and cannot yet prove causality, but suggest timing of omega-3 intervention may be critical
Study at a Glance
| Source | Alzheimer’s & Dementia |
| Study type | Cross-sectional observational analysis |
| Sample size | N = 841 adults |
| Population | Women and men with Alzheimer’s disease, and healthy controls |
| Country | Multiple European sites |
Lipid profiles in Alzheimer’s disease: women vs men
Mean blood omega-3 and unsaturated fat levels across study groups, based on high-resolution lipid profiling
Source: Alzheimer’s & Dementia, 2025 (PMID: 40832908) | Georgian Medical Journal News
The lipid signature of women’s Alzheimer’s risk
The study employed high-resolution lipid profiling to measure 170 different lipid species in blood plasma from four groups: women diagnosed with Alzheimer’s disease, men with Alzheimer’s disease, cognitively healthy women, and cognitively healthy men. The standout finding was qualitative: women with Alzheimer’s showed a sharp drop in the protective unsaturated lipids that are normally abundant in female blood, a pattern entirely absent in men with the disease.
Specifically, women with Alzheimer’s demonstrated lower circulating levels of omega-3-rich lipids and other polyunsaturated species. At the same time, blood biomarkers of neuronal damage and inflammation were elevated in these women, and those with the lowest omega-3 levels scored worse on objective memory testing. This constellation of findings—lipid depletion plus cognitive decline plus inflammatory markers—suggests that lipid dysregulation may be part of the mechanism driving cognitive loss in women.
Menopause, enzymes, and the loss of a biochemical advantage
The authors propose a mechanistic explanation rooted in sex hormones and brain chemistry. Healthy women normally accumulate higher brain concentrations of omega-3 polyunsaturated fats than men—a natural advantage that may protect against neurodegeneration. This higher female brain omega-3 content depends on two key processes: synthesis and transport.
During reproductive years, estrogen supports the enzyme FADS2, which catalyses the conversion of dietary alpha-linolenic acid (ALA) into long-chain omega-3s like docosahexaenoic acid (DHA). After menopause, when estrogen levels fall sharply, FADS2 activity declines. Simultaneously, the brain’s primary transporter for omega-3s—the protein MFSD2A—appears to weaken with age, reducing the efficiency with which the brain can accumulate these lipids from the blood. Together, these two changes strip away the biochemical shield that women had enjoyed.
Men do not experience this hormonal cliff and may rely on a different enzymatic architecture for brain omega-3 metabolism, explaining why they show no lipid depletion pattern in Alzheimer’s disease. This sex-specific vulnerability offers a potential explanation for the well-documented epidemiological observation that women comprise roughly two-thirds of Alzheimer’s disease cases worldwide.
Omega-3 dosing: prevention window matters more than treatment
The same research group conducted a concurrent meta-analysis of 58 randomised controlled trials examining the cognitive effects of omega-3 supplementation (EPA and DHA). The findings were nuanced and clinically important: supplementation at doses of 1,000–2,500 mg/day of combined EPA and DHA showed the most robust benefits for cognition, but only in specific populations.
The strongest effects emerged in prevention trials—studies of healthy, cognitively normal adults followed for fewer than 12 months. By contrast, trials that enrolled people already diagnosed with mild cognitive impairment or Alzheimer’s disease showed minimal to no benefit from omega-3 supplementation. This pattern hints that the window of opportunity may close once neurodegeneration is clinically evident, and that prevention or early intervention in at-risk groups (such as perimenopausal or postmenopausal women) may be where omega-3 therapy has the most promise.
Women with Alzheimer’s showed a 38% reduction in protective blood omega-3 lipids compared to healthy women, while men with Alzheimer’s showed no such decline. Omega-3 supplementation (1,000–2,500 mg/day EPA+DHA) showed strongest cognitive benefits in healthy adults, not in those already diagnosed with disease.
— Analysis from Alzheimer’s & Dementia (2025, PMID: 40832908) and meta-analysis of 58 RCTs (PMID: 40836005)
Limitations and the path forward
The study’s cross-sectional design is a critical limitation: the observation that women with Alzheimer’s have depleted omega-3 lipids does not prove that the lipid loss causes the disease. Reverse causality is possible—Alzheimer’s pathology itself could alter lipid metabolism. Additionally, plasma lipids are a proxy for brain lipids; the blood-brain barrier actively regulates what crosses, so peripheral lipid levels may not perfectly mirror brain concentrations.
Other confounders remain to be disentangled, including the use of hormone replacement therapy (HRT), which could theoretically preserve FADS2 activity and omega-3 synthesis. The study did not present stratified analyses by HRT use, leaving open the question of whether hormone replacement might partially mitigate the lipid deficit observed in postmenopausal women.
Despite these caveats, the findings represent a meaningful advance in understanding sex-specific Alzheimer’s biology. The convergence of lipid profiling data, biomarker evidence, cognitive scores, and a plausible mechanistic pathway suggests that future research should prioritise longitudinal, prospective studies of lipid trajectories in midlife women at risk of cognitive decline. Such work could identify a window for targeted omega-3 intervention before neurodegeneration becomes irreversible.
What this means
Frequently asked questions
Why do women get Alzheimer’s disease more often than men?
Multiple factors contribute. Women live longer on average, which increases cumulative disease risk. Beyond age, this new research suggests that loss of estrogen after menopause depletes the brain’s protective omega-3 lipids, a mechanism that does not affect men in the same way. Additionally, women’s cardiovascular biology, metabolic shifts, and genetic factors (including apolipoprotein E variants) differ from men’s, and these differences accumulate to raise female Alzheimer’s risk.
Should I take omega-3 supplements to prevent Alzheimer’s disease?
The evidence is most supportive for healthy adults without cognitive symptoms. A meta-analysis of 58 randomised controlled trials found that 1,000–2,500 mg/day of combined EPA and DHA showed cognitive benefits in prevention trials lasting up to 12 months. If you are concerned about cognitive risk—especially if you are a woman entering menopause or with a family history of dementia—discuss supplementation with your doctor. However, supplementation does not appear to reverse established cognitive impairment, so early intervention is key.
What is the difference between omega-3 from food versus supplements?
Both can raise blood and brain omega-3 levels, but the sources differ. Fatty fish (salmon, mackerel, sardines) provide EPA and DHA directly. Plant sources (flaxseed, walnuts, chia) provide ALA, which the body must convert to long-chain omega-3s via FADS2—a process that becomes less efficient after menopause. For this reason, direct supplementation with EPA and DHA capsules may be more reliable in postmenopausal women than relying on plant-based conversion. A balanced diet rich in both food sources and supplementation (if indicated) is optimal.
These findings add biological plausibility to the long-standing clinical observation that women bear a disproportionate burden of Alzheimer’s disease. As the global population ages, understanding and addressing the sex-specific mechanisms of neurodegeneration will be critical to designing effective prevention and treatment strategies. Future prospective studies should track lipid changes across the menopausal transition and test whether earlier omega-3 intervention can protect cognitive function in at-risk women. In the meantime, the evidence-based dosing guidance—1,000–2,500 mg/day EPA+DHA for healthy, cognitively normal individuals—provides a practical starting point for clinicians and patients to consider, particularly in the context of individualised risk assessment.
Source: Alzheimer’s & Dementia (2025, PMID: 40832908) and meta-analysis of 58 randomised controlled trials (PMID: 40836005); originally reported on New Studies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
